Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s10020-020-00211-0 http://scihub22266oqcxt.onion/10.1186/s10020-020-00211-0 32807075!7430134!32807075     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32807075&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Mol+Med 2020 ; 26 (1): 80 Nephropedia Template TP {{tp|p=32807075|t=2020. Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?|pdf=|usr=}}{{32807075}} gab.com Text Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19 JO: Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=32807075 #FOAvip Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1 receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall end-organ damage of this disease. Twit Text FOAVip Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19 ????Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=32807075 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32807075 #FOAvip English Wikipedia <ref>{{Cite pmid|32807075}}</ref> Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19? #MMPMID32807075 Namsolleck P; Moll GN Mol Med 2020[Aug]; 26 (1): 80 PMID32807075show ga Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1 receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall end-organ damage of this disease. |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/drug therapy[MESH] |Humans[MESH] |Imidazoles/pharmacology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/*metabolism[MESH] |Pneumonia, Viral/drug therapy[MESH] |Proto-Oncogene Mas[MESH] |Receptor, Angiotensin, Type 2/*agonists/metabolism[MESH]Does activation of the protective Renin-Angiotensin System have therap(epmc).pdf DeepDyve Pubget Overpricing